X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5069) 5069
Book Review (2024) 2024
Publication (449) 449
Conference Proceeding (19) 19
Book Chapter (13) 13
Dissertation (6) 6
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (4226) 4226
humans (3960) 3960
oncology (3632) 3632
chemotherapy (2633) 2633
female (2101) 2101
cancer (1750) 1750
antineoplastic combined chemotherapy protocols - therapeutic use (1701) 1701
aged (1642) 1642
middle aged (1592) 1592
male (1586) 1586
adult (1244) 1244
lung neoplasms - drug therapy (1242) 1242
treatment outcome (1230) 1230
phase-iii trial (1211) 1211
gemcitabine (1188) 1188
carcinoma, non-small-cell lung - drug therapy (1154) 1154
deoxycytidine - analogs & derivatives (1047) 1047
care and treatment (1013) 1013
cisplatin (856) 856
antineoplastic agents - therapeutic use (846) 846
phase-ii trial (828) 828
survival (814) 814
deoxycytidine - administration & dosage (773) 773
neoplasm staging (726) 726
antineoplastic combined chemotherapy protocols - adverse effects (692) 692
pharmacology & pharmacy (692) 692
paclitaxel (681) 681
lung neoplasms - pathology (673) 673
aged, 80 and over (669) 669
metastasis (657) 657
plus gemcitabine (644) 644
pancreatic cancer (627) 627
prognosis (627) 627
research (625) 625
trial (620) 620
disease-free survival (603) 603
1st-line treatment (587) 587
medicine & public health (586) 586
hematology, oncology and palliative medicine (585) 585
therapy (584) 584
carcinoma, non-small-cell lung - pathology (578) 578
lung cancer, non-small cell (565) 565
combination (562) 562
open-label (561) 561
carboplatin (557) 557
docetaxel (547) 547
randomized-trial (546) 546
survival rate (537) 537
drug therapy (536) 536
clinical trials (534) 534
lung cancer (531) 531
bevacizumab (529) 529
cell lung-cancer (505) 505
cisplatin - administration & dosage (479) 479
non-small cell lung cancer (479) 479
respiratory system (473) 473
survival analysis (469) 469
analysis (451) 451
pancreatic neoplasms - drug therapy (445) 445
health aspects (439) 439
carcinoma (431) 431
cancer therapies (425) 425
plus cisplatin (411) 411
breast cancer (407) 407
adjuvant chemotherapy (398) 398
animals (398) 398
cooperative-oncology-group (397) 397
retrospective studies (391) 391
clinical trials as topic (388) 388
antineoplastic agents (377) 377
neoplasm metastasis (375) 375
lung neoplasms - mortality (374) 374
multicenter (372) 372
cisplatin plus gemcitabine (371) 371
adenocarcinoma (363) 363
double-blind (360) 360
breast neoplasms - drug therapy (356) 356
antineoplastic combined chemotherapy protocols - administration & dosage (355) 355
antimitotic agents (354) 354
randomized controlled trials as topic (347) 347
carcinoma, non-small-cell lung - mortality (345) 345
pancreatic neoplasms - pathology (345) 345
phase-iii (339) 339
vinorelbine (328) 328
deoxycytidine - adverse effects (327) 327
growth-factor receptor (327) 327
tumors (327) 327
drug administration schedule (324) 324
phase-ii (322) 322
quality-of-life (322) 322
deoxycytidine - therapeutic use (321) 321
patients (319) 319
paclitaxel - administration & dosage (311) 311
carboplatin - administration & dosage (309) 309
clinical-trials (303) 303
supportive care (303) 303
surgery (295) 295
hematology (285) 285
chemotherapy, adjuvant (282) 282
quality of life (281) 281
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (4987) 4987
German (43) 43
French (40) 40
Spanish (4) 4
Polish (2) 2
Hungarian (1) 1
Italian (1) 1
Japanese (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 02/2013, Volume 119, Issue 3, pp. 540 - 547
BACKGROUND: Neoadjuvant chemotherapy improves the survival of patients with high-risk urothelial cancer. However, the lack of curative alternatives to... 
clinical trial | ifosfamide | neoadjuvant | bladder cancer | sequential | gemcitabine | urothelial cancer | doxorubicin | chemotherapy | surgery | PLUS GEMCITABINE | SURVIVAL | ADVANCED BLADDER-CANCER | PACLITAXEL | THERAPY | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | CYSTECTOMY | III TRIAL | Carcinoma, Transitional Cell - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Urothelium - pathology | Cisplatin - administration & dosage | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Deoxycytidine - adverse effects | Female | Doxorubicin - administration & dosage | Urinary Bladder Neoplasms - mortality | Drug Administration Schedule | Deoxycytidine - administration & dosage | Ifosfamide - adverse effects | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Urinary Bladder Neoplasms - surgery | Carcinoma, Transitional Cell - pathology | Ifosfamide - administration & dosage | Neoadjuvant Therapy - adverse effects | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Cisplatin - adverse effects | Aged | Carcinoma, Transitional Cell - surgery | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Doxorubicin - adverse effects | Neoadjuvant therapy | Care and treatment | Usage | Gemcitabine | Ifosfamide | Patient outcomes | Diagnosis | Health aspects | Doxorubicin | Urinary tract cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
British Journal of Cancer, ISSN 0007-0920, 12/2009, Volume 101, Issue 11, pp. 1853 - 1859
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 2017, Volume 18, Issue 5, pp. 565 - 571
Journal Article
Cancer, ISSN 0008-543X, 08/2006, Volume 107, Issue 3, pp. 599 - 605
Journal Article
Breast Cancer, ISSN 1340-6868, 7/2011, Volume 18, Issue 3, pp. 203 - 212
The primary objective of this multicenter, open-label, randomized, parallel, phase II selection trial was to compare the objective tumor response to biweekly... 
Medicine & Public Health | Diagnostic Radiology | Gemcitabine | Surgery | Paclitaxel | Carboplatin | Oncology | Breast cancer | Interventional Radiology | Imaging / Radiology | Surgical Oncology | Cisplatin | PLUS GEMCITABINE | MANAGEMENT | GUIDELINES | TOXICITY | COMBINATION | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY | ONCOLOGY | RECURRENT | REPEATING DOUBLET THERAPY | EXPOSURE | Anthracyclines - adverse effects | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cisplatin - administration & dosage | Carboplatin - adverse effects | Carcinoma, Ductal, Breast - drug therapy | Anthracyclines - administration & dosage | Adult | Carcinoma, Ductal, Breast - pathology | Deoxycytidine - adverse effects | Female | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Carboplatin - administration & dosage | Paclitaxel - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cisplatin - adverse effects | Breast Neoplasms - mortality | Neoplasm Staging | Deoxycytidine - analogs & derivatives | Medical colleges | Anthracyclines | Care and treatment | Oncology, Experimental | Clinical trials | Metastasis | Research | Antineoplastic agents | Antimitotic agents | Complications and side effects | Analysis | Product development | Drug therapy | Cancer | Index Medicus
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10018, pp. 545 - 557
Summary Background Nanoliposomal irinotecan showed activity in a phase 2 study in patients with metastatic pancreatic ductal adenocarcinoma previously treated... 
Internal Medicine | PLUS GEMCITABINE | SURVIVAL | 5-FLUOROURACIL | MEDICINE, GENERAL & INTERNAL | ADENOCARCINOMA | 2ND-LINE CHEMOTHERAPY | OXALIPLATIN | PEP02 | DOCETAXEL | CARCINOMA | FOLFIRI | Leucovorin - administration & dosage | Humans | Middle Aged | Male | Fatigue - chemically induced | Diarrhea - chemically induced | Pancreatic Neoplasms - drug therapy | Neoplasm Metastasis | Fluorouracil - administration & dosage | Leucovorin - adverse effects | Fluorouracil - adverse effects | Camptothecin - administration & dosage | Carcinoma, Pancreatic Ductal - mortality | Deoxycytidine - adverse effects | Female | Pancreatic Neoplasms - mortality | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Camptothecin - adverse effects | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Treatment Outcome | Carcinoma, Pancreatic Ductal - drug therapy | Vomiting - chemically induced | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Liposomes | Deoxycytidine - analogs & derivatives | Antimitotic agents | Medical colleges | Pancreatic cancer | Leucovorin | Product development | Research institutes | Metastasis | Antineoplastic agents | Analysis | Antigens | Chemotherapy | Medical prognosis | Clinical trials | Drug dosages | Cancer therapies | Tumors | Adenocarcinoma | Slopes | Therapy | Gemcitabine | Toxicity | Metastases | Nanoparticles | Randomization | Motivation | Vomiting | Safety management | Toxic diseases | Neutropenia | Folinic acid | Lymphatic system | Medical treatment | Diarrhea | FDA approval | Survival | Patients | Irinotecan | Acids | Equivalence | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2017, Volume 75, pp. 73 - 82
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 2015, Volume 75, Issue 4, pp. 683 - 690
Journal Article